Figure EV1. Inhibition of early response gene expression by lorlatinib in ALK‐driven neuroblastoma cells.

Lorlatinib‐induced gene expression changes of ARC, EGR1‐3, FOS and FOSB in NB cell lines that harbor ALK activating mutations. Data obtained from (Van den Eynden et al, 2018).